Table 3.
Maximum effect in each category
| n | Category A | Category B | Category C | Category D | p value | |
|---|---|---|---|---|---|---|
| GC | 92 | 13 | 20 | 36 | 23 | <0.0001 |
| CR | 1 | 1 | 0 | 0 | 0 | |
| PR | 14 | 12 | 2 | 0 | 0 | |
| SD | 47 | 0 | 15 | 27 | 5 | |
| PD | 30 | 0 | 3 | 9 | 18 | |
| GCS | 91 | 40 | 21 | 19 | 11 | <0.0001 |
| CR | 3 | 2 | 0 | 1 | 0 | |
| PR | 36 | 33 | 2 | 1 | 0 | |
| SD | 35 | 5 | 19 | 9 | 2 | |
| PD | 17 | 0 | 0 | 8 | 9 |
Best response was evaluated according to RECIST version 1.1 [19].
GC, conventional gemcitabine + cisplatin; GCS, biweekly gemcitabine + cisplatin + S-1; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RR, response rate; DCR, disease control rate.
Bold typeface indicates p < 0.1.